Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2000-03-30
2003-11-18
Caputa, Anthony C. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S338000, C435S326000, C530S388100
Reexamination Certificate
active
06649743
ABSTRACT:
This application claims benefit of foreign priority from Canada patent application 2,267,481, filed Mar. 30, 1999.
The present invention relates to a monoclonal antibody which demonstrates specific binding to human estrogen-responsive isoenzyme of Leucine Aminopeptidase (es-LAPase). The present invention also relates to the hybridoma cell line, designated as 7B6, and the monoclonal antibody produced by the same. The present invention further relates to a diagnostic system using the monoclonal antibody from the hybridoma cell line 7B6, to detect blood, serum or plasma levels of the estrogen responsive isoenzyme of Leucine Aminopeptidase. The antibody is particularly useful for rapid diagnostic tests for breast cancer.
BACKGROUND OF THE INVENTION
The identification and characterization of risk factors and their molecular implications in the pathophysiology of human diseases such as breast cancer is essential for designing efficient diagnostic assays and therapeutic compounds. Amongst the various risk factors associated with the onset of early events leading to Breast Cancer, estrogen and estrogen-like compounds with estrogenic mimicking activity remain the most important determinants in the early events and progression of breast carcinogenesis. Under normal physiological conditions, there are several tissues whereby estrogenic steroids have been shown to play a critical function. These include the development of the reproductive tract, particularly secondary organs, such as the mammary glands. In addition, estrogens are also involved in the fine regulation of bone growth, liver and cardiovascular function and the estrus cycle, most likely through the induction of cell proliferation in target tissues [Sutherland R. L. et al., pp. 197-215, Elsevier Science Publishing B. V., Amsterdam., Shekhar P. V. M., et al.,
J. NatL Cancer. Inst
., 89: 1774-1782.]. The response of such a variety of tissues to estrogen stimulation can explain in part its active role in the development and progression of different human carcinomas and in particular of Breast Cancer. Although the precise molecular mechanisms by which estrogen stimulation regulates various physiological functions requires further elucidation, this steroid is involved in both “immediate-early” and “early” events of cell function. In this regard, it appears that immediate early events induced by estrogen lead to an increased cellular proliferation most likely through the reduction in the cell cycle by accelerating the rate at which cells progress from the G
l
phase towards the S phase. Recently, it has been proposed that estrogen promotes cellular proliferation by co-activating at similar estrogen concentrations, the expression of cyclin Dl-Cdk4 and cyclin E-Cdk2, two critical and potentially interrelated G
l
regulatory peptides [Prall, O. W. J., et al.,
J. Biol. Chem
., 272: 10882-10894.].
Diagnostic assays are available for breast cancer. For example, imaging techniques such as ultrasounds and x-rays (mammographies) are widely used to detect tumours. These imaging techniques, however, suffer from a limitation in the resolution of the image which prevents the detection of tumours below a certain size.
Histological analysis of biopsies is also a common procedure for the diagnosis of breast cancer and this technique relies on identification of visible phenotypes of the cells. However, this analysis is somewhat subjective and depends on the skill of the examiner.
Molecular diagnostics assays are also available. Among the most widely relied upon is an assay which measures estrogen and progesterone receptors on cells obtained from biopsies. This assay is useful to determine whether a particular type of cancer will be responsive to hormonal therapy.
Flow cytometry can also be used to measure parameters, such as DNA content and the proportion of cells in a particular phase of the cell cycle, that correlates with the presence of cancerous cells.
However, histology, estrogen and progesterone receptor analysis and flow cytometry all require that biopsies be taken and that the sample be extensively processed.
Therefore, there is a need for more rapid and less invasive methods of diagnosing breast cancer. In particular, sensitive assays to detect the presence of cellular markers, preferably in the blood, which reflect the presence of metastasis are desirable. Even more desirable, given the prominent role of estrogen in the progression of breast cancer, are cellular markers, other than estrogen and progesterone receptors, responsive to estrogen.
SUMMARY OF THE INVENTION
The present invention relates to a monoclonal antibody which demonstrates specific binding to human estrogen-stimulated leucine aminopeptidase (es-LAPase). The present invention further relates to a diagnostic system using the monoclonal antibody to detect blood, serum, plasma or tissue levels of the es-LAPase.
Thus, according to the present invention there is provided a monoclonal antibody which is specific for es-LAPase.
In a further embodiment of the present invention there is provided a method of detecting breast cancer in a patient by determining the level of es-LAPase in a sample.
This invention is also directed to a method for detecting a metastatic cancer in a patient by determining the level of es-LAPase in a sample.
REFERENCES:
patent: 5179008 (1993-01-01), Kahan et al.
Pulido-Cejudo, Gabrial, et al, “NDP-Kinase And Leucine Aminopeptidase: Two Prognostic Factors Of Cellular Invasiveness and Metastasis of Human Brain Tumours”, Journal of Cellular Biochemistry Supplement, (1994) vol. 0, No. 18D, pp. 111. Meeting Info.: Keystone Symposium On Molecular Basis Of Cancer Therapy Tamarron, Colorado, USA Mar. 4-10, 1994, XP000916389.
Database WPI; Section Ch, Week 198133; Derwent Publications Ltd., London, GB; Class B04, AN 1981-59499D; XP002145124 and JP 56 078600 A (Eiken Kagaku KK), Jun. 27, 1981 (Jun. 27, 1981).
Pulido-Cejudo, Gabriel et al: “Critical Interdependency: From the Role of Estrogen on Breast Cancer to the Susceptibility of Women Towards HIV Infection”, NATO Sci. Ser., Ser. A (1999), 311 (Intermolecular Cross-Talk in Tumor Metastasis), 123-136, XP000916826.
Database Chemabs [Online] Chemical Abstracts Service, Columbus, Ohio, US; Niinobe, Michio: “Studies on Leucine Aminopeptidase in Normal and Cancerous Tissues in Man”, retrieved from STN, Database accession No. 84:178003, XP002145123.
Weber H: “[Significance of Leucine Aminopeptidase]. Die Bedeutung der Leucin-Aminopeptidase.” Deutsche Medizinische Wochenschrift, (Jan. 24, 1969) 94 (4) 181-4., XP000916687, p. 183.
Deng, Jing T. et al: “Purification of Circulating Liver Plasma Membrane Fragments Using A Monoclonal Antileucine Aminopeptidase Antibody”, Hepatology (Philadelphia) (1996), 23 (3), 445-54, XP000916789.
PCT International Search Report; PCT Application No. PCT/CA 00/00332; filed Mar. 30, 2000.
Deng J.T. et al; “Purification of Circulating Liver Plasma Membrane Fragments Using A Monoclonal Antileucine Aminopeptidase Antibody”;Hepatology1996 Mar.; 23(3):445-54
Dunzendorfer U. and Drahovsky D.; “Estrogens in Carcinoma of the Prostate: Effects on Enzymes and Nad Polypeptide Hormones”;Arzneim.-Forsch./Drug Res.1978; 28(1), Heft 6:1027-1030.
Gupta S.K. et al: “Serum Leucine Aminopeptidase Estimation: A Sensitive Prognostic Indicator of Invasiveness In Breast Carcinoma”;Indian J Pathol Microbiol1989 Oct.; 32(4):301-5.
Kobayashi H. et al; “[The Significance of Serum Leucine Aminopeptidase (P-LAP) Determination in the Gynecological Malignancies]”;Nippon Sanka Fujinka Gakkai Zasshi1985 May;37(5):696-702.
Kohno H. et al; “Immunoaffinity Purification and Characterization of Leucine Aminopeptidase From Human Liver”;J Biol Chem1986 Aug. 15;261(23):10744-8.
Leyhausen G. et al; “Immunochemical Identification of the Cell Surface Bound Leucine Aminopeptidase,The Target Enzyme for the Immunostimulant Bestatin”;J Antibiot(Tokyo) 1983 Jun.;36(6):728-34.
Oettgen H.C. and Taylor A.; “Purification, Preliminary Characterization, and Immunological Comparison of Hog Lens Leu
Caputa Anthony C.
Her Majesty the Queen in right of Canada as represented by the
Thompson Hine LLP
Yu Misook
LandOfFree
Monoclonal antibody against estrogen stimulated leucine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody against estrogen stimulated leucine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody against estrogen stimulated leucine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3159287